Amgen Gets Cost-Sharing, MedImmune A Pipeline Boost In Five-Antibody Collaboration

Amgen and the AstraZeneca biologics subsidiary will co-develop and commercialize five monoclonal antibodies in inflammation and respiratory indications, led by brodalumab, which recently posted impressive Phase II data in psoriasis.